SLC1A5 and hepatocellular carcinoma: To determine whether SLC1A5 can predict the response of HBV-related HCC patients to immune checkpoint inhibitor therapies, the expression levels of 8 immune checkpoint-related genes were analyzed in high-SLC1A5 and low-SLC1A5 HBV-related HCC patients.